XML 10 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 21, 2025
Jun. 28, 2024
Cover [Abstract]      
Entity Registrant Name PLUS THERAPEUTICS, INC.    
Entity Central Index Key 0001095981    
Trading Symbol PSTV    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Entity Current Reporting Status Yes    
Entity Filer Category Non-accelerated Filer    
Entity Public Float     $ 8.2
Entity Common Stock, Shares Outstanding   16,999,626  
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Security Exchange Name NASDAQ    
Entity File Number 001-34375    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 33-0827593    
Entity Address, Address Line One 2710 REED ROAD    
Entity Address, Address Line Two SUITE 160    
Entity Address, City or Town HOUSTON    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 77051    
City Area Code 737    
Local Phone Number 255-7194    
Document Annual Report true    
Document Transition Report false    
Auditor Firm ID 243    
Auditor Name BDO USA, P.C.    
Auditor Location Austin, Texas    
Auditor Opinion

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Plus Therapeutics, Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the years then ended and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

    
Documents Incorporated by Reference [Text Block]

Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders, which will be filed with the United States Securities and Exchange Commission within 120 days of December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K.